AMIS Plus - National Registry of Acute Myocardial Infarction in Switzerland
NCT ID: NCT01305785
Last Updated: 2013-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60000 participants
OBSERVATIONAL
1997-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Myocardial Infarction: Prognostic and Therapeutic Evaluation
NCT03883711
French Registry of Acute Coronary Syndrome
NCT00673036
MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial
NCT03135275
OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction
NCT04988672
Myocardial Infarction Register of the Saarland
NCT02961985
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To Maintain a Nationwide Registry
* An ongoing nationwide registry (databank) of acute coronary syndromes
* Description of the patient population with acute coronary syndromes
* Description of characteristics of treatment and hospitalization
* Description of outcomes 3- and 12-months after admission for ACS
* Epidemiological studies, e.g. definition of risk factors of patients with acute coronary syndromes, hospital mortality, time and cost-effective strategies as well as outcome measures
2. Quality Control
* Evaluation of compliance with guidelines for the medical care of acute coronary syndromes
* Internal quality control through regular feedback and benchmarking
Methods
All Swiss hospitals admitting patients with acute coronary syndrome are eligible. Data are collected on demographics, risk factors, symptoms, laboratory results, invasive therapy, complications and medication.
Since the start in January 1997, the method of data collection has continuously improved in order to suit the different needs and technological advancements of the participating hospitals. Participants can either complete paper questionnaires and send them directly to the AMIS Plus Data Center at the Institute of Social and Preventive Medicine in Zurich where these questionnaires are then checked and entered online or they can enter data directly online (AMIS online questionnaire). Data security has a high priority. Participant identification (code for hospital and physician) and a password are required to access the data entry form and send data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria: Since January 2012, patients with unstable angina are no longer included.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
University Hospital, Geneva
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER
University Hospital, Basel, Switzerland
OTHER
Triemli Hospital
OTHER
Kantonsspital Baden
OTHER
Cantonal Hospital of St. Gallen
OTHER
University Hospital Freiburg
OTHER
Cantonal Hospital, Frauenfeld
OTHER
Hospital Centre Biel/Bienne
OTHER
Spital Lachen AG
OTHER
Cardiocentro Ticino
OTHER
Luzerner Kantonsspital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Paul Erne
AMIS Plus Steering Committee President
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Erne, MD
Role: STUDY_DIRECTOR
AMIS Plus Data Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dragana Radovanovic
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Radovanovic D, Erne P. AMIS Plus: Swiss registry of acute coronary syndrome. Heart. 2010 Jun;96(12):917-21. doi: 10.1136/hrt.2009.192302.
Roberto M, Hoepli A, Cattaneo M, Radovanovic D, Rickli H, Erne P, Pedrazzini GB, Moccetti M. Patients With AMI and Severely Reduced LVEF, a Well-Defined, Still Extremely Vulnerable Population (Insights from AMIS Plus Registry). Am J Cardiol. 2023 Aug 1;200:190-201. doi: 10.1016/j.amjcard.2023.05.027. Epub 2023 Jun 20.
Roberto M, Radovanovic D, Butta C, Tersalvi G, Krull J, Erne P, Rickli H, Pedrazzini GB, Moccetti M. Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction. Interact Cardiovasc Thorac Surg. 2021 Oct 29;33(5):687-694. doi: 10.1093/icvts/ivab159.
Bruggmann C, Iglesias JF, Gex-Fabry M, Fesselet R, Vogt P, Sadeghipour F, Voirol P. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study. Am J Cardiovasc Drugs. 2020 Feb;20(1):105-115. doi: 10.1007/s40256-019-00361-5.
Radovanovic D, Seifert B, Roffi M, Urban P, Rickli H, Pedrazzini G, Erne P. Gender differences in the decrease of in-hospital mortality in patients with acute myocardial infarction during the last 20 years in Switzerland. Open Heart. 2017 Nov 14;4(2):e000689. doi: 10.1136/openhrt-2017-000689. eCollection 2017.
Bertel N, Witassek F, Puhan M, Erne P, Rickli H, Naegeli B, Pedrazzini G, Stauffer JC, Radovanovic D. Management and outcome of patients with acute myocardial infarction presenting with pacemaker rhythm. Int J Cardiol. 2017 Mar 1;230:604-609. doi: 10.1016/j.ijcard.2016.12.047. Epub 2016 Dec 20.
Schoenenberger AW, Radovanovic D, Windecker S, Iglesias JF, Pedrazzini G, Stuck AE, Erne P; AMIS Plus Investigators. Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. Eur Heart J. 2016 Apr 21;37(16):1304-11. doi: 10.1093/eurheartj/ehv698. Epub 2016 Jan 12.
Erne P, Radovanovic D, Seifert B, Bertel O, Urban P; AMIS Plus Investigators. Outcome of patients admitted with acute coronary syndrome on palliative treatment: insights from the nationwide AMIS Plus Registry 1997-2014. BMJ Open. 2015 Mar 2;5(3):e006218. doi: 10.1136/bmjopen-2014-006218.
Wildi K, Cuculi F, Twerenbold R, Marxer T, Rubini Gimenez M, Reichlin T, Haaf P, Monsch R, Marsch S, Hunziker P, Bingisser R, Osswald S, Erne P, Mueller C. Incidence and timing of serious arrhythmias after early revascularization in non ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2015 Aug;4(4):359-64. doi: 10.1177/2048872614557230. Epub 2014 Oct 27.
Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, Puhan MA, Erne P; AMIS Plus Investigators. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. Heart. 2014 Feb;100(4):288-94. doi: 10.1136/heartjnl-2013-304588. Epub 2013 Nov 1.
Related Links
Access external resources that provide additional context or updates about the study.
AMIS Plus Registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMIS Plus
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.